Title: A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Authors: Cleary, James M.; Calvo, Emiliano; Moreno, Victor; Juric, Dejan; Shapiro, Geoffrey I.; Vanderwal, Carol Ann; Hu, Beibei; Gifford, Maryella; Barch, David; Roberts-Rapp, Lisa; Ansell, Peter J.; Xiong, Hao; Ocampo, Christopher; Tolcher, Anthony W.
Publication: Investigational New Drugs, 2020, Vol 38, Issue 5, p1483
ISSN: 0167-6997
Publication type: Academic Journal
DOI: 10.1007/s10637-020-00908-3

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

Cleary, James M.; Calvo, Emiliano; Moreno, Victor; Juric, Dejan; Shapiro, Geoffrey I.; Vanderwal, Carol Ann; Hu, Beibei; Gifford, Maryella; Barch, David; Roberts-Rapp, Lisa; Ansell, Peter J.; Xiong, Hao; Ocampo, Christopher; Tolcher, Anthony W.